Women Heavily Burdened by Alzheimer's Disease

Alzheimer's disease will place an increasing burden on women according to new reports.

November is Long-Term Care Awareness Month and even the U.S. Congress has urged "the people of the United States to recognize (this) as an opportunity to learn more about the potential risks and costs … and the options available."   Alzheimer's is a leading cause of need for long-term care.

Over 10 million American females either have Alzheimer's disease (AD) or look after a patient with the disease, according to the American Association for Long-Term Care Insurance. 

Two thirds (65%) of all Alzheimer's patients are female (3 million in America) and 6.7 million women care for somebody with the disease, says The Shriver Report, a collaboration between California's First Lady Mary Shriver and The Alzheimer's Association.

By the year 2050 approximately 8 million women will have AD in the US.

Here are some of the highlights of the report:

·         Over 10 million American females either have AD or look after a patient with the disease

·         65% of Alzheimer's patients are female

·         60% of caregivers of Alzheimer's patients are female

·         40% of caregivers who are female say they have no choice

·         One third of all female caregivers are caring for somebody with AD around the clock, seven days a week

·         The impact of AD on business, families and government is estimated to be $300 billion annually

·         Nearly two-thirds of caregivers who also have a job say they have no choice but to get to work late, clock off early and sometimes take time off to care for somebody with AD.

Despite hundreds of clinical trials and millions spent on research, Alzheimer's disease is still incurable. Researchers and experts continue to hope, and say we are making progress. Even so, there is a feeling among most Americans that scientific progress is too slow. When compared to innovative breakthroughs that have occurred in diabetes, stroke, cancer and heart disease, Americans rank Alzheimer's at the bottom of the list.

Vitamin B May Help Dementia Alzheimer's Disease

A new study reveals that elderly individuals with mild cognitive impairment who take huge doses of B vitamins everyday may reduce the rate at which their brains shrink by 50%, resulting in a much slower progression toward dementia, and eventually Alzheimer's disease.

According to the findings of studies conducted by researchers from Oxford University, England, in an article published in Plos One (Public Library of Science One), this two-year clinical trial is the largest ever which examined the effect of B vitamins on "mild cognitive impairment" (MCI).

Individuals with MCI have a higher risk of progression to Alzheimer's disease and other forms of dementia notes Jesse Slome, director of the American Association for Long-Term Care Insurance the industry's trade group.

"People with mild cognitive impairment can function in everyday activities, but they may have problems with memory, such as recalling people's names, losing the flow of a conversation, and not remembering where they left things," Slome explains. Approximately 16% of individuals aged over 70 years are affected by mild cognitive impairment.

David Smith, University Department of Pharmacology and Department of Physiology, Anatomy & Genetics, University of Oxford, trial co-leader, said:

The single-center, randomized, double-blind controlled trial involved 168 volunteers who all had been diagnosed with mild cognitive impairment. One group received high daily doses of vitamins B6 (0.5 mg/d) and B12 (20 mg/d), as well as folic acid (0.8 mg/d). This was 300 times the recommended daily intake for B12, 15 times daily recommended amounts of B6, and 4 times daily recommended intake of folic acid.

The other group received a placebo (tablets without any active ingredients). Treatment lasted 24 months.

The principal outcome measure was the change in the rate of atrophy of the whole brain, assessed by serial volumetric MRI scans.

The researchers found that the B vitamin with folic acid group had an average brain shrinkage of 0.76% per year. The placebo group had an average brain shrinkage of 1.08% per year.

Those with the highest homocysteine blood levels at the start of the trial who took the B vitamins and folic acid experienced half the brain shrinkage compared to individuals with the highest homocysteine blood levels at the start and who received the placebo.

To learn more about long-term care insurance and receive a free, no obligation quote for this protection, visit the Association's Consumer Information Center. Click here now.